Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glycomimetics Inc (NQ: GLYC )

0.2710 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 231
Open 0.2710
Bid (Size) 0.2708 (2)
Ask (Size) 0.2773 (7)
Prev. Close 0.2710
Today's Range 0.2710 - 0.2710
52wk Range 0.2560 - 3.530
Shares Outstanding 64,464,412
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
From GlycoMimetics, Inc.
Via Business Wire
GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024
GLYC stock results show that GlycoMimetics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-90.04%
-90.04%
1 Month
-85.39%
-85.39%
3 Month
-90.66%
-90.66%
6 Month
-82.96%
-82.96%
1 Year
-84.43%
-84.43%

More News

Read More
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Earnings Outlook For GlycoMimetics
Via Benzinga
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink
Via Benzinga
Why Is Acutus Medical (AFIB) Stock Down 41% Today?
Via InvestorPlace
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023
Via InvestorPlace
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts
Via Talk Markets
Earnings Scheduled For March 27, 2024
Via Benzinga
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
From GlycoMimetics, Inc.
Via Business Wire
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From GlycoMimetics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
From GlycoMimetics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.